Researchers have identified 13 novel genetic errors associated with an increased risk of developing glioma, in the largest ever study of the disease.
Brain and neurologic
Researchers have demonstrated the feasibility of utilizing tumor sequencing when guiding chemotherapy in early-breast cancer patients.
Dr Hafez Halawani talks to Oncology Central regarding the predictive and prognostic potential of tumor location in metastatic colorectal cancer – a debate that was perpetuated with the presentation of the Venook et al study at the 2016 ASCO meeting.
Explore the role of epigenetics in neuroendocrine prostate cancer in this peer-reviewed article from Epigenomics.
This review article from our partner journal Hepatic Oncology explores the immunology of hepatocellular carcinoma and details clinical trials investigating the efficacy of immune checkpoint blockade in the disease.
The authors review standard practices, current trends and controversies, and promising future therapies in muscle-invasive and metastatic bladder urothelial cancers.
Scientists have developed a urine test to predict the emergence of cervical cancer, for which preliminary studies confirm its accuracy and potential cost savings with regard to screening.
Head and neck
A calcium ion channel present in T cells has been identified by researchers as a potential target to reduce growth in head and neck cancer.
In this interview find out about Anthony Nolan’s research strategy, breakthroughs that have aided the advancement of stem cell transplantation, how third-generation sequencing for HLA typing may improve donor-recipient matching and the direction that Alejandro Madrigal envisions Anthony Nolan’s research will take in the coming years.
A pro-metastatic protein interaction has been identified in lung cancer and could present a potential future target.
This review article from Future Oncology explores the roles of miRNAs in pancreatic cancer development and the potential of miRNA-based therapeutics.
New investigation highlights preclinical efficacy of a combination of immune checkpoint inhibitors and therapies targeting myeloid-derived suppressor cells in advanced prostate cancer.
To mark Rare Disease Day, Oncology Central brings you an exclusive opinion piece written by two of the principal investigators of a pivotal immunotherapy clinical trial designed specifically for rare cancer patients.
This systematic review provides a comparative assessment of the efficacy and toxicity of combination or single-agent ipilimumab as immunotherapy of advanced melanoma.